Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 booster trial of VLPCOV-04 versus Comirnaty XBB.1.5 in healthy adults
jRCT2051230141Phase 3Completed
- Sponsor
- VLP Therapeutics Japan
- Start
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing VLPCOV-04 booster with Comirnaty XBB.1.5 booster (2 arms). Primary endpoints: Neutralizing antibody GMT against Omicron XBB.1.5 at Week 4 and Neutralizing antibody seroresponse rate against Omicron XBB.1.5 at Week 4. Started Dec 2023; status: completed.
02
Drugs
VLPCOV-04tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2051230141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230141.